- You can view the full Pfizer Ratings Report.
- You can view the full JPMorgan Chase Ratings Report.
Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
Here's what you need to know now for Wed., Aug. 9.
All eyes are on Pfizer in the months ahead.